Authors: Böhmer, Gabriele M.¹; Drollmann, Anton²; Gleiter, Christoph H.¹; Nave, Rüdiger³

Source: Clinical Pharmacokinetics, Volume 47, Number 5, 2008 , pp. 343-349(7)

Publisher: Adis International

Abstract:

Background and objectives: Cytochrome P450 (CYP) 3A4 isoenzyme has been identified in vitro as the key enzyme to metabolize desisobutyryl-ciclesonide (des-CIC), the pharmacologically active metabolite of the inhaled corticosteroid ciclesonide. This pharmacokinetic drug-drug interaction study was conducted to confirm this major metabolic pathway in vivo by using the strong CYP3A4 inhibitor ketoconazole, and to assess the effect of ketoconazole on the pharmacokinetics of ciclesonide and des-CIC.

Methods: Fourteen healthy adults participated in this open-label, nonrandomized, fixed sequence, two-period, repeated-dose pharmacokinetic study. During the first 7-day treatment period, the subjects orally inhaled ciclesonide 320 µg once daily. During the second 7-day treatment period, the subjects continued with the same dose of orally inhaled ciclesonide and concomitantly received oral ketoconazole 400 mg once daily. Pharmacokinetic profiles for ciclesonide and des-CIC were obtained on day 7 of each study period.

Results: For the parent compound, ciclesonide, no changes in the pharmacokinetic parameter estimates - the area under the serum concentration-time curve during the dosage interval (AUC_τ), maximum serum concentration (C_max) and time to reach the C_max - were observed. In contrast, the AUC_τ and C_max of des-CIC increased approximately 3.5-fold and 2-fold under the influence of the CYP3A4 inhibitor ketoconazole.

Conclusions: The CYP3A4 pathway is the major pathway for biotransformation of the active metabolite of ciclesonide in humans. While elimination of des-CIC was reduced by strong CYP3A4 inhibitor coadministration in vivo, activation of the parent compound ciclesonide to des-CIC was not affected. Dose adjustment is not necessary when ciclesonide needs to be coadministered with ketoconazole, because the potency of an inhaled corticosteroid is mediated by topical concentrations in the lung and because ciclesonide has a very low potential to produce systemic adverse effects.

Keywords: Antiasthmatics; Ciclesonide; Ciclesonide; Cytochrome P450 inhibitors; Drug interactions; Ketoconazole

Document Type: Research article

Affiliations: 1: 1 Department of Clinical Pharmacology, University Hospital of Tübingen, Tübingen, Germany 2: 2 Respiration, Altana Pharma AG, Konstanz, Germany 3: 3 Pharmacometrics and Pharmacokinetics, Nycomed GmbH, Konstanz, Germany

Publication date: 2008-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Böhmer, Gabriele M. ;  Drollmann, Anton ;  Gleiter, Christoph H. ;  Nave, Rüdiger

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers